Your browser doesn't support javascript.
loading
Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis.
Thibodeau, My Linh; Zhao, Eric Y; Reisle, Caralyn; Ch'ng, Carolyn; Wong, Hui-Li; Shen, Yaoqing; Jones, Martin R; Lim, Howard J; Young, Sean; Cremin, Carol; Pleasance, Erin; Zhang, Wei; Holt, Robert; Eirew, Peter; Karasinska, Joanna; Kalloger, Steve E; Taylor, Greg; Majounie, Elisa; Bonakdar, Melika; Zong, Zusheng; Bleile, Dustin; Chiu, Readman; Birol, Inanc; Gelmon, Karen; Lohrisch, Caroline; Mungall, Karen L; Mungall, Andrew J; Moore, Richard; Ma, Yussanne P; Fok, Alexandra; Yip, Stephen; Karsan, Aly; Huntsman, David; Schaeffer, David F; Laskin, Janessa; Marra, Marco A; Renouf, Daniel J; Jones, Steven J M; Schrader, Kasmintan A.
Afiliación
  • Thibodeau ML; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6H 3N1, Canada.
  • Zhao EY; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Reisle C; Hereditary Cancer Program, BC Cancer, Vancouver, British Columbia V5Z 1H5, Canada.
  • Ch'ng C; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Wong HL; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Shen Y; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Jones MR; Department of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada.
  • Lim HJ; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Young S; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Cremin C; Department of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada.
  • Pleasance E; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia V6T 2B5, Canada.
  • Zhang W; Cancer Genetics and Genomics Laboratory, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada.
  • Holt R; Hereditary Cancer Program, BC Cancer, Vancouver, British Columbia V5Z 1H5, Canada.
  • Eirew P; Pancreas Centre BC, Vancouver, British Columbia V5Z 1L8, Canada.
  • Karasinska J; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Kalloger SE; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Taylor G; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6H 3N1, Canada.
  • Majounie E; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Bonakdar M; Department of Molecular Oncology, BC Cancer, Vancouver, British Columbia V5Z 1L3, Canada.
  • Zong Z; Pancreas Centre BC, Vancouver, British Columbia V5Z 1L8, Canada.
  • Bleile D; Pancreas Centre BC, Vancouver, British Columbia V5Z 1L8, Canada.
  • Chiu R; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
  • Birol I; The Canadian Centre for Applied Research in Cancer Control, Vancouver, British Columbia V5Z 1L3, Canada.
  • Gelmon K; Department of Pathology and Laboratory Medicine, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada.
  • Lohrisch C; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Mungall KL; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Mungall AJ; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Moore R; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Ma YP; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Fok A; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Yip S; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6H 3N1, Canada.
  • Karsan A; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Huntsman D; Department of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada.
  • Schaeffer DF; Department of Medical Oncology, BC Cancer, Vancouver, British Columbia V5Z 4E6, Canada.
  • Laskin J; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Marra MA; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Renouf DJ; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Jones SJM; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
  • Schrader KA; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
Article en En | MEDLINE | ID: mdl-30833417
ABSTRACT
We report a case of early-onset pancreatic ductal adenocarcinoma in a patient harboring biallelic MUTYH germline mutations, whose tumor featured somatic mutational signatures consistent with defective MUTYH-mediated base excision repair and the associated driver KRAS transversion mutation p.Gly12Cys. Analysis of an additional 730 advanced cancer cases (N = 731) was undertaken to determine whether the mutational signatures were also present in tumors from germline MUTYH heterozygote carriers or if instead the signatures were only seen in those with biallelic loss of function. We identified two patients with breast cancer each carrying a pathogenic germline MUTYH variant with a somatic MUTYH copy loss leading to the germline variant being homozygous in the tumor and demonstrating the same somatic signatures. Our results suggest that monoallelic inactivation of MUTYH is not sufficient for CG>AT transversion signatures previously linked to MUTYH deficiency to arise (N = 9), but that biallelic complete loss of MUTYH function can cause such signatures to arise even in tumors not classically seen in MUTYH-associated polyposis (N = 3). Although defective MUTYH is not the only determinant of these signatures, MUTYH germline variants may be present in a subset of patients with tumors demonstrating elevated somatic signatures possibly suggestive of MUTYH deficiency (e.g., COSMIC Signature 18, SigProfiler SBS18/SBS36, SignatureAnalyzer SBS18/SBS36).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Neoplasias de la Mama / Carcinoma Ductal Pancreático / ADN Glicosilasas / Mutación Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Cold Spring Harb Mol Case Stud Año: 2019 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Neoplasias de la Mama / Carcinoma Ductal Pancreático / ADN Glicosilasas / Mutación Tipo de estudio: Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Cold Spring Harb Mol Case Stud Año: 2019 Tipo del documento: Article País de afiliación: Canadá